Pfizer was also developing a twice-daily formulation of the drug, which showed promising weight loss, but was plagued by ...

To what extent will health clinics go to keep selling in-demand weight-loss drugs now that the FDA has outlawed cheaper ...

People are buying semaglutide and tirzepatide, the key ingredients in Ozempic and Zepbound, from unconventional sources. Doctors have safety concerns.

A U.S. senator said a GLP-1 drug changed his life — and now he’s calling for widespread access to anti-obesity medications.

The study finds better A1c lowering and weight reduction, but an expert clinician says practical issues may pose barriers.

Eli Lilly (LLY) leads with groundbreaking tirzepatide (Mounjaro/Zepbound), while Hims & Hers Health (HIMS) faces challenges.

Hims & Hers is expanding access to Eli Lilly's branded weight loss drug Zepbound and diabetes drug Mounjaro as well as ...

Lexicon Pharmaceuticals, headquartered in The Woodlands, announced it will exclusively license its drug LX9851 to the maker ...

India's anti-obesity drug market has surged, growing over fourfold in five years, reaching ₹576 crore by March 2025, driven ...

Tirzepatide switchers also had a 5.1 cm greater ... Bayer, Dexcom, Endogenex, Novo Nordisk, Pfizer, Sanofi, and Xeris Pharmaceutical. Other co-authors also reported relationships with Eli Lilly ...

Hims & Hers Health (HIMS) is trying its best to stay relevant in the multi-billion dollar obesity treatment market. Despite a few setbacks ...